Septerna is poised for a pivotal catalyst with upcoming Phase 1 data for SEP-631, targeting mast cell-driven diseases via ...
Q4 2025 Earnings Call February 25, 2026 8:30 AM ESTCompany ParticipantsLindsey Christen - Chief Administrative ...
LONDON, UK / ACCESS Newswire / February 25, 2026 / The Company announces that on 24 February 2026 it purchased the following ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results